Risperidone Plasma Levels, Clinical Response and Side-Effects

MJ Schwarz , I Spellmann , A Müller-Arends , M Strassnig
Pharmacopsychiatry 38 ( 01) 80

2005
Cognitive benefits of quetiapine versus risperidone in schizophrenia

I Spellmann , M Riedel , N Müller , M Strassnig
Pharmacopsychiatry 38 ( 05)

1
2005
Weight gain over 1 year in medicated first-break psychotic patients and medication-free controls

M Strassnig , M Keshavan , J Miewald , R Ganguli
BIOLOGICAL PSYCHIATRY 59 ( 8) 60S -60S

2006
Elektrokonvul-sionstherapie bei Neuroleptika-Therapie-Refraktarität schizophrener Erkrankungen

M Riedel , M Strassnig , HJ Möller , N Müller
Elektrokonvulsionstherapie. Klinische und wissenschaftliche Aspekte 428 -443

4
2004
Aripiprazol Fuhrt ein neuer Wirkungsmechanismus zu einer neuen Qualitat in der Schizophrenie-Therapie?

M Riedel , M Strassnig , K-U Kuhn , N Muller
PSYCHOPHARMAKOTHERAPIE-STUTTGART- 10 ( 2) 46 -54

4
2003
Die Stellung der Depot-Neuroleptika aus heutiger Sicht

M Riedel , M Strassnig , H-J Möller , N Müller
Schizophrenie: Langzeitverlauf und Langzeittherapie 215 -231

2
2004
The Correlation of Self-reported and Clinician Rated-Cognition with Other Assessments in Schizophrenia

Dante Durand , M Strassnig , F Gould , G Vargas
BIOLOGICAL PSYCHIATRY 75 ( 9) 336S -337S

2014
Aripiprazole and brexpiprazole

Rolando Gonzalez , M Strassnig
Schatzberg A, Nemeroff C. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 5a ed Arlington VA (USA): American Psychiatric Publishing 731 -54

4
2017
Quetiapine (Seroquel) has equivalent efficacy and superior tolerability to risperidone in the treating the negative symptoms of schizophrenia

M Riedel , N Müller , M Strassnig , I Spellmann
Poster presented at the XXIV Collegium Internationale Neuropsychopharmacologicum

1
2004
Aripiprazole-can a new pharmacological mode of action lead to a new quality in the treatment of schizophrenia?

M Riedel , M Strassnig , KU Kuhn , N Muller
Psychopharmakotherapie 10 ( 2) 46 -54

1
2003
Clozapine/olanzapine/risperidone

M Strassnig
Reactions Weekly &NA; ( 1151) 12

2007
Cardiovascular fitness, exercise capacity, and substrate metabolism in schizophrenia

M Strassnig , B Goodpaster , G Grove , R Ganguli
The International Journal of Neuropsychopharmacology 11 145 -145

2008
Low cardiovascular fitness level in community-dwelling patients with schizophrenia

M Strassnig , G Grove , BH Goodpaster , R Ganguli
SCHIZOPHRENIA BULLETIN 33 ( 2) 606 -606

2007
Prevention of weight gain program for first-episode of psychosis patients

R Miller , R Ganguli , JS Brar , M Strassnig
ACTA PSYCHIATRICA SCANDINAVICA 114 68 -68

2006
Efficacy of quetiapine versus risperidone in the treatment of schizophrenia with predominantly negative symptoms

M Riedel , HJ Moller , M Strassnig , I Spellmann
EUROPEAN PSYCHIATRY 19 90S -90S

2004
Immunogenetic investigations supporting the TH2-hypothesis of schizophrenia

MJ Schwarz , M Riedel , M Kroenig , C Minov
AMERICAN JOURNAL OF MEDICAL GENETICS 114 ( 7) 872 -872

2002
Decreased T cellular immune response in schizophrenic patients.

M RIEDEL , I SPELLMANN , M SCHWARZ , M STRASSNIG
Journal of Psychiatric Research 41 ( 1) 3 -7

61
2007
Self-reported social functioning and social cognition in schizophrenia and bipolar disorder: Using ecological momentary assessment to identify the origin of bias.

Colin A. Depp , Martin T. Strassnig , Amy E. Pinkham , Robert A. Ackerman
Schizophrenia Research 230 17 -23

23
2021
Evidence for avolition in bipolar disorder? A 30-day ecological momentary assessment comparison of daily activities in bipolar disorder and schizophrenia.

Colin A. Depp , Martin T. Strassnig , Amy E. Pinkham , Raeanne Moore
Psychiatry Research-neuroimaging 300 113924 -113924

1
2021